Brought to you by 
Jasper Therapeutics launches with $35mm Series A round to develop HCT compound from Amgen; $14.1mm tranche added
29 Jan 2020
Executive Summary
| Jasper Therapeutics Inc. (hematopoietic cell transplants (HCTs) and gene therapies) launched with a $35mm Series A round co-led by Abingworth and Qiming Venture Partners. Surveyor Capital (an equities business of Citadel Capital) and Alexandria Venture Investments also participated. |
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Jasper Therapeutics launches with $35mm Series A round to develop HCT compound from Amgen; $14.1mm tranche added
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice